Psychedelic Drug Development
Extensive expedited program submissions experience with global health authorities.
MMS is always available and responsive to my inquiries and requests, whether they are related to a psychedelics drug development project or to any other matter.
Psychedelic drug development is experiencing intense and renewed interest from the pharmaceutical industry, and the potential for these therapies to target areas of urgent unmet need. Opportunities exist for prepared sponsors to take advantage of expedited approval pathways and reach the market ahead of the competition.
With our extensive knowledge of expedited programs, psychedelics, and psychiatric indications, we can help clinical trial sponsors gain new drug approval by:
- Achieving initial fast track and breakthrough designations
- Leveraging designations to accelerate clinical development though early and effective health authority interactions
- Preparing for the challenging timelines associated with Priority Review, rolling submissions, and Advisory Committees
- Sharing industry best practices and submission experience
Why choose MMS?
Expedited pathways impose additional urgency on every discipline within drug development. At MMS, we are uniquely positioned to address the challenges that are inherent in psychedelics drug development through 4 key differentiators:
- Experience developing landmark psychedelics NDA submission
- Proactive focus on data quality to ensure efficiency and smart decision-making
- Strong clinical understanding of treatment from beginning to end of psychedelic therapeutics and drug development
- Cross-functional working relationships and approaches to fill gaps across teams and disciplines
Whether preparing a Phase 1 CMC package or a Module 3 build for marketing application, our expert CMC consultants and writers will help you navigate GMP requirements, right of reference approaches, and unique challenges such as guidelines for botanical drug development.
Our team of nonclinical strategists, writers, and data specialists will help you achieve agreement from global health authorities and conduct your pre-clinical program with confidence through the following:
- Effective use of Type-D meetings to obtain early agreement on the use of published literature and reference submissions to effectively leverage prior nonclinical and clinical data in support of IND enabling studies.
- Early discussions of relevant non-clinical requirements to ensure study designs are appropriate to planned indication and clinical dosing regimen.
- Worry-free IND preparation from experienced nonclinical writers and strategists.
- Create SOPs proactively to ensure that compliance needs are met
- Build credible development program for potential partners and investors
- Develop regulatory and compliance strategy in parallel for synergistic benefits
- Strategic consulting and direct regulatory communication
- Coordinating submissions in tandem with your clinical or regulatory groups
- Consolidating data entry and uploads to CTIS, leveraging our CTIS tracker as a reliable reference for all updates
- Efficient portal monitoring and document management
- A seasoned team adept at personal protected data (PPD) and company confidential information (CCI) redactions
- Orchestrating reviews with your clinical, regulatory, and legal entities
- PoCs skilled at guiding, facilitating, and pinpointing reasons for CCI
- Crafting consistent dossiers reusable for other disclosure needs like ClinicalTrials.gov, Health Canada PRCI, and EMA Policy 0070 submissions
- Comprehensive dossier disclosure support
- Skilled medical writers utilize lean authoring techniques and practices in line with CTR
- GAP analysis and refining your templates for portal compatibility
- Precision authoring to limit the reliance on PPD and CCI
Suggested For You
webinar
September 26th, 2024
Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance
regulatory intelligence
August 27th, 2024
Recent Guidance on Diversity Action Planning
regulatory intelligence
August 26th, 2024
Oncology Programs at the FDA
regulatory intelligence
August 26th, 2024
Three Key Take Reflections on the Recent Donanemab Approval
webinar
September 12th, 2024
No Stone Unturned: Optimizing the Use of Expedited Pathways and Oncology Center of Excellence Programs to Optimize Drug Development in Oncology
regulatory intelligence
August 9th, 2024
FDA Updates 2024 Language Access Plan
regulatory intelligence
August 3rd, 2024
EMA Launches New Pilot Program for Orphan Medical Devices
perspectives
July 30th, 2024
The Critical Role of Quality Control (QC) – Medical Writing and Beyond
regulatory intelligence
July 26th, 2024
Key Decision Points for Recent Oncology Approvals
regulatory intelligence
July 24th, 2024
Comments Open for Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products
perspectives
July 23rd, 2024
PSI 2024 Ignited Conversations on External Data Sources, Requirements for Estimands, and Bayesian Methodology for Statisticians in Pharma
news
July 17th, 2024
Industry Veteran Ben Dudley Joins MMS as Chief Commercial Officer (CCO) to Drive Continued Growth for the Data-focused Clinical Research Organization